nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—ALB—Tacrolimus—atopic dermatitis	0.232	0.429	CbGbCtD
Valsartan—ALB—Prednisone—atopic dermatitis	0.0942	0.174	CbGbCtD
Valsartan—CYP2C9—Loratadine—atopic dermatitis	0.0916	0.169	CbGbCtD
Valsartan—CYP2C9—Diphenhydramine—atopic dermatitis	0.0916	0.169	CbGbCtD
Valsartan—CYP2C9—Dexamethasone—atopic dermatitis	0.0317	0.0586	CbGbCtD
Valsartan—AGTR1—ACE Inhibitor Pathway—CMA1—atopic dermatitis	0.00354	0.101	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—FOXP3—atopic dermatitis	0.000956	0.0272	CbGpPWpGaD
Valsartan—AGTR1—Peptide GPCRs—CCR3—atopic dermatitis	0.00089	0.0253	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL13—atopic dermatitis	0.000818	0.0233	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCL22—atopic dermatitis	0.000797	0.0227	CbGpPWpGaD
Valsartan—AGTR1—Peptide GPCRs—CXCR3—atopic dermatitis	0.000778	0.0222	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL17A—atopic dermatitis	0.000753	0.0214	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCL27—atopic dermatitis	0.00071	0.0202	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL5—atopic dermatitis	0.0007	0.0199	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCL17—atopic dermatitis	0.000637	0.0181	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL22—atopic dermatitis	0.000534	0.0152	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCL11—atopic dermatitis	0.000513	0.0146	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL10—atopic dermatitis	0.000512	0.0146	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL4—atopic dermatitis	0.000498	0.0142	CbGpPWpGaD
Valsartan—AGTR1—Peptide GPCRs—CCR5—atopic dermatitis	0.000488	0.0139	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL27—atopic dermatitis	0.000476	0.0136	CbGpPWpGaD
Valsartan—Malnutrition—Hydrocortisone—atopic dermatitis	0.000452	0.00107	CcSEcCtD
Valsartan—Neutropenia—Prednisone—atopic dermatitis	0.000451	0.00106	CcSEcCtD
Valsartan—Haemoglobin—Dexamethasone—atopic dermatitis	0.000446	0.00105	CcSEcCtD
Valsartan—Haemoglobin—Betamethasone—atopic dermatitis	0.000446	0.00105	CcSEcCtD
Valsartan—Erectile dysfunction—Prednisone—atopic dermatitis	0.000444	0.00105	CcSEcCtD
Valsartan—Haemorrhage—Betamethasone—atopic dermatitis	0.000443	0.00105	CcSEcCtD
Valsartan—Haemorrhage—Dexamethasone—atopic dermatitis	0.000443	0.00105	CcSEcCtD
Valsartan—Angiopathy—Methylprednisolone—atopic dermatitis	0.000442	0.00104	CcSEcCtD
Valsartan—Nausea—Mometasone—atopic dermatitis	0.000441	0.00104	CcSEcCtD
Valsartan—Immune system disorder—Methylprednisolone—atopic dermatitis	0.00044	0.00104	CcSEcCtD
Valsartan—Mediastinal disorder—Methylprednisolone—atopic dermatitis	0.000439	0.00104	CcSEcCtD
Valsartan—Vision blurred—Prednisolone—atopic dermatitis	0.000436	0.00103	CcSEcCtD
Valsartan—Hypersensitivity—Tacrolimus—atopic dermatitis	0.000435	0.00103	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL17—atopic dermatitis	0.000427	0.0122	CbGpPWpGaD
Valsartan—Mental disorder—Methylprednisolone—atopic dermatitis	0.000427	0.00101	CcSEcCtD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—TRPV3—atopic dermatitis	0.000427	0.0121	CbGpPWpGaD
Valsartan—Malnutrition—Methylprednisolone—atopic dermatitis	0.000424	0.001	CcSEcCtD
Valsartan—Asthenia—Tacrolimus—atopic dermatitis	0.000424	0.001	CcSEcCtD
Valsartan—Angioedema—Prednisolone—atopic dermatitis	0.000423	0.000997	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCR3—atopic dermatitis	0.000419	0.0119	CbGpPWpGaD
Valsartan—Pruritus—Tacrolimus—atopic dermatitis	0.000418	0.000986	CcSEcCtD
Valsartan—Dysgeusia—Triamcinolone—atopic dermatitis	0.000416	0.000983	CcSEcCtD
Valsartan—Vertigo—Prednisolone—atopic dermatitis	0.000415	0.00098	CcSEcCtD
Valsartan—Syncope—Prednisolone—atopic dermatitis	0.000415	0.000979	CcSEcCtD
Valsartan—Angioedema—Hydrocortisone—atopic dermatitis	0.000413	0.000974	CcSEcCtD
Valsartan—Back pain—Triamcinolone—atopic dermatitis	0.000411	0.000971	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—CCL22—atopic dermatitis	0.000407	0.0116	CbGpPWpGaD
Valsartan—Loss of consciousness—Prednisolone—atopic dermatitis	0.000406	0.000959	CcSEcCtD
Valsartan—Vertigo—Hydrocortisone—atopic dermatitis	0.000406	0.000957	CcSEcCtD
Valsartan—Syncope—Hydrocortisone—atopic dermatitis	0.000405	0.000956	CcSEcCtD
Valsartan—Diarrhoea—Tacrolimus—atopic dermatitis	0.000404	0.000954	CcSEcCtD
Valsartan—Angiopathy—Betamethasone—atopic dermatitis	0.000402	0.000949	CcSEcCtD
Valsartan—Angiopathy—Dexamethasone—atopic dermatitis	0.000402	0.000949	CcSEcCtD
Valsartan—Loss of consciousness—Hydrocortisone—atopic dermatitis	0.000397	0.000937	CcSEcCtD
Valsartan—Alopecia—Dexamethasone—atopic dermatitis	0.000392	0.000924	CcSEcCtD
Valsartan—Alopecia—Betamethasone—atopic dermatitis	0.000392	0.000924	CcSEcCtD
Valsartan—Dizziness—Tacrolimus—atopic dermatitis	0.000391	0.000922	CcSEcCtD
Valsartan—Angioedema—Triamcinolone—atopic dermatitis	0.000389	0.000917	CcSEcCtD
Valsartan—Haemoglobin—Prednisone—atopic dermatitis	0.000388	0.000915	CcSEcCtD
Valsartan—Angioedema—Methylprednisolone—atopic dermatitis	0.000388	0.000915	CcSEcCtD
Valsartan—Haemorrhage—Prednisone—atopic dermatitis	0.000386	0.000911	CcSEcCtD
Valsartan—Myalgia—Hydrocortisone—atopic dermatitis	0.000384	0.000907	CcSEcCtD
Valsartan—Anxiety—Hydrocortisone—atopic dermatitis	0.000383	0.000904	CcSEcCtD
Valsartan—Vertigo—Triamcinolone—atopic dermatitis	0.000382	0.000902	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—atopic dermatitis	0.000382	0.000901	CcSEcCtD
Valsartan—Syncope—Triamcinolone—atopic dermatitis	0.000381	0.0009	CcSEcCtD
Valsartan—Vertigo—Methylprednisolone—atopic dermatitis	0.000381	0.0009	CcSEcCtD
Valsartan—Syncope—Methylprednisolone—atopic dermatitis	0.000381	0.000898	CcSEcCtD
Valsartan—Connective tissue disorder—Prednisone—atopic dermatitis	0.000379	0.000895	CcSEcCtD
Valsartan—AGTR1—G alpha (q) signalling events—NPS—atopic dermatitis	0.000378	0.0108	CbGpPWpGaD
Valsartan—AGTR1—G alpha (q) signalling events—TAC1—atopic dermatitis	0.000378	0.0108	CbGpPWpGaD
Valsartan—Oedema—Prednisolone—atopic dermatitis	0.000377	0.000891	CcSEcCtD
Valsartan—Anaphylactic shock—Prednisolone—atopic dermatitis	0.000377	0.000891	CcSEcCtD
Valsartan—Vomiting—Tacrolimus—atopic dermatitis	0.000376	0.000886	CcSEcCtD
Valsartan—Loss of consciousness—Triamcinolone—atopic dermatitis	0.000374	0.000882	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—NPS—atopic dermatitis	0.000373	0.0106	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—TAC1—atopic dermatitis	0.000373	0.0106	CbGpPWpGaD
Valsartan—Loss of consciousness—Methylprednisolone—atopic dermatitis	0.000373	0.00088	CcSEcCtD
Valsartan—Rash—Tacrolimus—atopic dermatitis	0.000373	0.000879	CcSEcCtD
Valsartan—Dermatitis—Tacrolimus—atopic dermatitis	0.000372	0.000878	CcSEcCtD
Valsartan—Shock—Prednisolone—atopic dermatitis	0.000371	0.000876	CcSEcCtD
Valsartan—Cough—Triamcinolone—atopic dermatitis	0.000371	0.000876	CcSEcCtD
Valsartan—Headache—Tacrolimus—atopic dermatitis	0.00037	0.000873	CcSEcCtD
Valsartan—Anaphylactic shock—Hydrocortisone—atopic dermatitis	0.000369	0.00087	CcSEcCtD
Valsartan—Oedema—Hydrocortisone—atopic dermatitis	0.000369	0.00087	CcSEcCtD
Valsartan—Infection—Hydrocortisone—atopic dermatitis	0.000366	0.000864	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CXCR3—atopic dermatitis	0.000366	0.0104	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CCL27—atopic dermatitis	0.000363	0.0103	CbGpPWpGaD
Valsartan—Shock—Hydrocortisone—atopic dermatitis	0.000363	0.000856	CcSEcCtD
Valsartan—Myalgia—Triamcinolone—atopic dermatitis	0.000362	0.000854	CcSEcCtD
Valsartan—Nervous system disorder—Hydrocortisone—atopic dermatitis	0.000361	0.000853	CcSEcCtD
Valsartan—Myalgia—Methylprednisolone—atopic dermatitis	0.000361	0.000852	CcSEcCtD
Valsartan—Arthralgia—Methylprednisolone—atopic dermatitis	0.000361	0.000852	CcSEcCtD
Valsartan—Anxiety—Methylprednisolone—atopic dermatitis	0.00036	0.000849	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	0.000359	0.000846	CcSEcCtD
Valsartan—Skin disorder—Hydrocortisone—atopic dermatitis	0.000358	0.000845	CcSEcCtD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK8—atopic dermatitis	0.000355	0.0101	CbGpPWpGaD
Valsartan—Dry mouth—Triamcinolone—atopic dermatitis	0.000354	0.000835	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—CASP8—atopic dermatitis	0.000354	0.0101	CbGpPWpGaD
Valsartan—Angioedema—Dexamethasone—atopic dermatitis	0.000353	0.000832	CcSEcCtD
Valsartan—Angioedema—Betamethasone—atopic dermatitis	0.000353	0.000832	CcSEcCtD
Valsartan—Anorexia—Hydrocortisone—atopic dermatitis	0.000351	0.000829	CcSEcCtD
Valsartan—Nausea—Tacrolimus—atopic dermatitis	0.000351	0.000828	CcSEcCtD
Valsartan—Angiopathy—Prednisone—atopic dermatitis	0.00035	0.000826	CcSEcCtD
Valsartan—Immune system disorder—Prednisone—atopic dermatitis	0.000349	0.000823	CcSEcCtD
Valsartan—Anaphylactic shock—Triamcinolone—atopic dermatitis	0.000347	0.000819	CcSEcCtD
Valsartan—Oedema—Triamcinolone—atopic dermatitis	0.000347	0.000819	CcSEcCtD
Valsartan—Vertigo—Dexamethasone—atopic dermatitis	0.000347	0.000818	CcSEcCtD
Valsartan—Vertigo—Betamethasone—atopic dermatitis	0.000347	0.000818	CcSEcCtD
Valsartan—Anaphylactic shock—Methylprednisolone—atopic dermatitis	0.000346	0.000817	CcSEcCtD
Valsartan—Syncope—Dexamethasone—atopic dermatitis	0.000346	0.000816	CcSEcCtD
Valsartan—Syncope—Betamethasone—atopic dermatitis	0.000346	0.000816	CcSEcCtD
Valsartan—Infection—Triamcinolone—atopic dermatitis	0.000345	0.000814	CcSEcCtD
Valsartan—Hypotension—Hydrocortisone—atopic dermatitis	0.000344	0.000813	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL11—atopic dermatitis	0.000344	0.00981	CbGpPWpGaD
Valsartan—Infection—Methylprednisolone—atopic dermatitis	0.000344	0.000812	CcSEcCtD
Valsartan—Shock—Triamcinolone—atopic dermatitis	0.000341	0.000806	CcSEcCtD
Valsartan—Insomnia—Prednisolone—atopic dermatitis	0.000341	0.000805	CcSEcCtD
Valsartan—Alopecia—Prednisone—atopic dermatitis	0.000341	0.000805	CcSEcCtD
Valsartan—Shock—Methylprednisolone—atopic dermatitis	0.000341	0.000804	CcSEcCtD
Valsartan—Nervous system disorder—Methylprednisolone—atopic dermatitis	0.00034	0.000801	CcSEcCtD
Valsartan—Loss of consciousness—Dexamethasone—atopic dermatitis	0.000339	0.0008	CcSEcCtD
Valsartan—Loss of consciousness—Betamethasone—atopic dermatitis	0.000339	0.0008	CcSEcCtD
Valsartan—Paraesthesia—Prednisolone—atopic dermatitis	0.000339	0.0008	CcSEcCtD
Valsartan—Mental disorder—Prednisone—atopic dermatitis	0.000338	0.000798	CcSEcCtD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—atopic dermatitis	0.000338	0.00962	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NPS—atopic dermatitis	0.000338	0.00962	CbGpPWpGaD
Valsartan—Skin disorder—Methylprednisolone—atopic dermatitis	0.000336	0.000794	CcSEcCtD
Valsartan—Malnutrition—Prednisone—atopic dermatitis	0.000336	0.000793	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Hydrocortisone—atopic dermatitis	0.000336	0.000792	CcSEcCtD
Valsartan—Insomnia—Hydrocortisone—atopic dermatitis	0.000333	0.000787	CcSEcCtD
Valsartan—Paraesthesia—Hydrocortisone—atopic dermatitis	0.000331	0.000781	CcSEcCtD
Valsartan—Myalgia—Betamethasone—atopic dermatitis	0.000329	0.000775	CcSEcCtD
Valsartan—Myalgia—Dexamethasone—atopic dermatitis	0.000329	0.000775	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR3—atopic dermatitis	0.000328	0.00933	CbGpPWpGaD
Valsartan—Anxiety—Dexamethasone—atopic dermatitis	0.000327	0.000772	CcSEcCtD
Valsartan—Anxiety—Betamethasone—atopic dermatitis	0.000327	0.000772	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—CCL17—atopic dermatitis	0.000325	0.00926	CbGpPWpGaD
Valsartan—Dyspepsia—Hydrocortisone—atopic dermatitis	0.000324	0.000766	CcSEcCtD
Valsartan—Hypotension—Methylprednisolone—atopic dermatitis	0.000324	0.000764	CcSEcCtD
Valsartan—Decreased appetite—Hydrocortisone—atopic dermatitis	0.00032	0.000756	CcSEcCtD
Valsartan—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	0.000318	0.000751	CcSEcCtD
Valsartan—Fatigue—Hydrocortisone—atopic dermatitis	0.000318	0.00075	CcSEcCtD
Valsartan—Vision blurred—Prednisone—atopic dermatitis	0.000317	0.000747	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Triamcinolone—atopic dermatitis	0.000316	0.000746	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Methylprednisolone—atopic dermatitis	0.000315	0.000744	CcSEcCtD
Valsartan—Anaphylactic shock—Betamethasone—atopic dermatitis	0.000315	0.000743	CcSEcCtD
Valsartan—Oedema—Dexamethasone—atopic dermatitis	0.000315	0.000743	CcSEcCtD
Valsartan—Oedema—Betamethasone—atopic dermatitis	0.000315	0.000743	CcSEcCtD
Valsartan—Anaphylactic shock—Dexamethasone—atopic dermatitis	0.000315	0.000743	CcSEcCtD
Valsartan—Insomnia—Triamcinolone—atopic dermatitis	0.000314	0.000741	CcSEcCtD
Valsartan—Insomnia—Methylprednisolone—atopic dermatitis	0.000313	0.000739	CcSEcCtD
Valsartan—Infection—Betamethasone—atopic dermatitis	0.000313	0.000738	CcSEcCtD
Valsartan—Infection—Dexamethasone—atopic dermatitis	0.000313	0.000738	CcSEcCtD
Valsartan—Paraesthesia—Triamcinolone—atopic dermatitis	0.000312	0.000735	CcSEcCtD
Valsartan—Paraesthesia—Methylprednisolone—atopic dermatitis	0.000311	0.000734	CcSEcCtD
Valsartan—Shock—Betamethasone—atopic dermatitis	0.00031	0.000731	CcSEcCtD
Valsartan—Shock—Dexamethasone—atopic dermatitis	0.00031	0.000731	CcSEcCtD
Valsartan—Dyspnoea—Triamcinolone—atopic dermatitis	0.000309	0.00073	CcSEcCtD
Valsartan—Nervous system disorder—Dexamethasone—atopic dermatitis	0.000309	0.000729	CcSEcCtD
Valsartan—Nervous system disorder—Betamethasone—atopic dermatitis	0.000309	0.000729	CcSEcCtD
Valsartan—Thrombocytopenia—Betamethasone—atopic dermatitis	0.000308	0.000728	CcSEcCtD
Valsartan—Thrombocytopenia—Dexamethasone—atopic dermatitis	0.000308	0.000728	CcSEcCtD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—SLC11A1—atopic dermatitis	0.000308	0.00877	CbGpPWpGaD
Valsartan—Angioedema—Prednisone—atopic dermatitis	0.000307	0.000724	CcSEcCtD
Valsartan—Dyspepsia—Triamcinolone—atopic dermatitis	0.000306	0.000721	CcSEcCtD
Valsartan—Dyspepsia—Methylprednisolone—atopic dermatitis	0.000305	0.000719	CcSEcCtD
Valsartan—Vertigo—Prednisone—atopic dermatitis	0.000302	0.000712	CcSEcCtD
Valsartan—Gastrointestinal pain—Hydrocortisone—atopic dermatitis	0.000301	0.000711	CcSEcCtD
Valsartan—Syncope—Prednisone—atopic dermatitis	0.000301	0.000711	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—IFNG—atopic dermatitis	0.000301	0.00857	CbGpPWpGaD
Valsartan—Anorexia—Betamethasone—atopic dermatitis	0.0003	0.000708	CcSEcCtD
Valsartan—Anorexia—Dexamethasone—atopic dermatitis	0.0003	0.000708	CcSEcCtD
Valsartan—Urticaria—Prednisolone—atopic dermatitis	0.0003	0.000707	CcSEcCtD
Valsartan—Fatigue—Triamcinolone—atopic dermatitis	0.000299	0.000706	CcSEcCtD
Valsartan—Fatigue—Methylprednisolone—atopic dermatitis	0.000299	0.000704	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CXCL10—atopic dermatitis	0.000296	0.00842	CbGpPWpGaD
Valsartan—Loss of consciousness—Prednisone—atopic dermatitis	0.000295	0.000697	CcSEcCtD
Valsartan—Hypotension—Dexamethasone—atopic dermatitis	0.000294	0.000694	CcSEcCtD
Valsartan—Hypotension—Betamethasone—atopic dermatitis	0.000294	0.000694	CcSEcCtD
Valsartan—Urticaria—Hydrocortisone—atopic dermatitis	0.000293	0.000691	CcSEcCtD
Valsartan—Abdominal pain—Hydrocortisone—atopic dermatitis	0.000291	0.000688	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Dexamethasone—atopic dermatitis	0.000287	0.000677	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Betamethasone—atopic dermatitis	0.000287	0.000677	CcSEcCtD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—TRPV3—atopic dermatitis	0.000287	0.00816	CbGpPWpGaD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR3—atopic dermatitis	0.000286	0.00816	CbGpPWpGaD
Valsartan—Arthralgia—Prednisone—atopic dermatitis	0.000286	0.000675	CcSEcCtD
Valsartan—Myalgia—Prednisone—atopic dermatitis	0.000286	0.000675	CcSEcCtD
Valsartan—Anxiety—Prednisone—atopic dermatitis	0.000285	0.000673	CcSEcCtD
Valsartan—Insomnia—Dexamethasone—atopic dermatitis	0.000285	0.000672	CcSEcCtD
Valsartan—Insomnia—Betamethasone—atopic dermatitis	0.000285	0.000672	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	0.000284	0.00067	CcSEcCtD
Valsartan—Gastrointestinal pain—Methylprednisolone—atopic dermatitis	0.000283	0.000668	CcSEcCtD
Valsartan—Paraesthesia—Betamethasone—atopic dermatitis	0.000283	0.000667	CcSEcCtD
Valsartan—Paraesthesia—Dexamethasone—atopic dermatitis	0.000283	0.000667	CcSEcCtD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—atopic dermatitis	0.000281	0.008	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR3—atopic dermatitis	0.000281	0.00799	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—CXCL8—atopic dermatitis	0.00028	0.00797	CbGpPWpGaD
Valsartan—Hypersensitivity—Prednisolone—atopic dermatitis	0.000278	0.000656	CcSEcCtD
Valsartan—Dyspepsia—Betamethasone—atopic dermatitis	0.000277	0.000654	CcSEcCtD
Valsartan—Dyspepsia—Dexamethasone—atopic dermatitis	0.000277	0.000654	CcSEcCtD
Valsartan—Urticaria—Triamcinolone—atopic dermatitis	0.000276	0.000651	CcSEcCtD
Valsartan—Urticaria—Methylprednisolone—atopic dermatitis	0.000275	0.000649	CcSEcCtD
Valsartan—Anaphylactic shock—Prednisone—atopic dermatitis	0.000274	0.000647	CcSEcCtD
Valsartan—Oedema—Prednisone—atopic dermatitis	0.000274	0.000647	CcSEcCtD
Valsartan—Abdominal pain—Methylprednisolone—atopic dermatitis	0.000274	0.000646	CcSEcCtD
Valsartan—Decreased appetite—Betamethasone—atopic dermatitis	0.000274	0.000646	CcSEcCtD
Valsartan—Decreased appetite—Dexamethasone—atopic dermatitis	0.000274	0.000646	CcSEcCtD
Valsartan—Infection—Prednisone—atopic dermatitis	0.000272	0.000643	CcSEcCtD
Valsartan—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	0.000272	0.000642	CcSEcCtD
Valsartan—Gastrointestinal disorder—Betamethasone—atopic dermatitis	0.000272	0.000642	CcSEcCtD
Valsartan—Hypersensitivity—Hydrocortisone—atopic dermatitis	0.000272	0.000641	CcSEcCtD
Valsartan—Fatigue—Betamethasone—atopic dermatitis	0.000272	0.000641	CcSEcCtD
Valsartan—Fatigue—Dexamethasone—atopic dermatitis	0.000272	0.000641	CcSEcCtD
Valsartan—Shock—Prednisone—atopic dermatitis	0.00027	0.000637	CcSEcCtD
Valsartan—Nervous system disorder—Prednisone—atopic dermatitis	0.000269	0.000635	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—IL1B—atopic dermatitis	0.000268	0.00764	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL2—atopic dermatitis	0.000267	0.00761	CbGpPWpGaD
Valsartan—Skin disorder—Prednisone—atopic dermatitis	0.000266	0.000629	CcSEcCtD
Valsartan—Asthenia—Hydrocortisone—atopic dermatitis	0.000264	0.000624	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—CCL11—atopic dermatitis	0.000262	0.00747	CbGpPWpGaD
Valsartan—Anorexia—Prednisone—atopic dermatitis	0.000261	0.000617	CcSEcCtD
Valsartan—Pruritus—Hydrocortisone—atopic dermatitis	0.000261	0.000615	CcSEcCtD
Valsartan—Gastrointestinal pain—Dexamethasone—atopic dermatitis	0.000258	0.000608	CcSEcCtD
Valsartan—Gastrointestinal pain—Betamethasone—atopic dermatitis	0.000258	0.000608	CcSEcCtD
Valsartan—Hypersensitivity—Triamcinolone—atopic dermatitis	0.000256	0.000603	CcSEcCtD
Valsartan—Hypersensitivity—Methylprednisolone—atopic dermatitis	0.000255	0.000602	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCL5—atopic dermatitis	0.000255	0.00725	CbGpPWpGaD
Valsartan—Diarrhoea—Hydrocortisone—atopic dermatitis	0.000252	0.000595	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—NPS—atopic dermatitis	0.00025	0.00713	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—TAC1—atopic dermatitis	0.00025	0.00713	CbGpPWpGaD
Valsartan—Urticaria—Betamethasone—atopic dermatitis	0.00025	0.00059	CcSEcCtD
Valsartan—Urticaria—Dexamethasone—atopic dermatitis	0.00025	0.00059	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Prednisone—atopic dermatitis	0.00025	0.00059	CcSEcCtD
Valsartan—Dizziness—Prednisolone—atopic dermatitis	0.00025	0.000589	CcSEcCtD
Valsartan—Asthenia—Triamcinolone—atopic dermatitis	0.000249	0.000588	CcSEcCtD
Valsartan—Abdominal pain—Betamethasone—atopic dermatitis	0.000249	0.000587	CcSEcCtD
Valsartan—Abdominal pain—Dexamethasone—atopic dermatitis	0.000249	0.000587	CcSEcCtD
Valsartan—Asthenia—Methylprednisolone—atopic dermatitis	0.000248	0.000586	CcSEcCtD
Valsartan—Insomnia—Prednisone—atopic dermatitis	0.000248	0.000585	CcSEcCtD
Valsartan—Paraesthesia—Prednisone—atopic dermatitis	0.000246	0.000581	CcSEcCtD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	0.000246	0.007	CbGpPWpGaD
Valsartan—Pruritus—Triamcinolone—atopic dermatitis	0.000246	0.000579	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR3—atopic dermatitis	0.000245	0.00699	CbGpPWpGaD
Valsartan—Pruritus—Methylprednisolone—atopic dermatitis	0.000245	0.000578	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—CCL5—atopic dermatitis	0.000244	0.00695	CbGpPWpGaD
Valsartan—Dizziness—Hydrocortisone—atopic dermatitis	0.000244	0.000575	CcSEcCtD
Valsartan—Dyspepsia—Prednisone—atopic dermatitis	0.000241	0.00057	CcSEcCtD
Valsartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—atopic dermatitis	0.000239	0.0068	CbGpPWpGaD
Valsartan—Decreased appetite—Prednisone—atopic dermatitis	0.000238	0.000563	CcSEcCtD
Valsartan—Rash—Prednisolone—atopic dermatitis	0.000238	0.000561	CcSEcCtD
Valsartan—Dermatitis—Prednisolone—atopic dermatitis	0.000238	0.000561	CcSEcCtD
Valsartan—Diarrhoea—Methylprednisolone—atopic dermatitis	0.000237	0.000559	CcSEcCtD
Valsartan—Fatigue—Prednisone—atopic dermatitis	0.000236	0.000558	CcSEcCtD
Valsartan—Headache—Prednisolone—atopic dermatitis	0.000236	0.000558	CcSEcCtD
Valsartan—Constipation—Prednisone—atopic dermatitis	0.000235	0.000553	CcSEcCtD
Valsartan—Vomiting—Hydrocortisone—atopic dermatitis	0.000234	0.000553	CcSEcCtD
Valsartan—Rash—Hydrocortisone—atopic dermatitis	0.000232	0.000548	CcSEcCtD
Valsartan—Dermatitis—Hydrocortisone—atopic dermatitis	0.000232	0.000548	CcSEcCtD
Valsartan—Headache—Hydrocortisone—atopic dermatitis	0.000231	0.000545	CcSEcCtD
Valsartan—Dizziness—Triamcinolone—atopic dermatitis	0.00023	0.000542	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—CCR5—atopic dermatitis	0.000229	0.00653	CbGpPWpGaD
Valsartan—Dizziness—Methylprednisolone—atopic dermatitis	0.000229	0.00054	CcSEcCtD
Valsartan—Asthenia—Betamethasone—atopic dermatitis	0.000226	0.000533	CcSEcCtD
Valsartan—Asthenia—Dexamethasone—atopic dermatitis	0.000226	0.000533	CcSEcCtD
Valsartan—Gastrointestinal pain—Prednisone—atopic dermatitis	0.000224	0.000529	CcSEcCtD
Valsartan—Nausea—Prednisolone—atopic dermatitis	0.000224	0.000529	CcSEcCtD
Valsartan—Pruritus—Dexamethasone—atopic dermatitis	0.000223	0.000526	CcSEcCtD
Valsartan—Pruritus—Betamethasone—atopic dermatitis	0.000223	0.000526	CcSEcCtD
Valsartan—Vomiting—Triamcinolone—atopic dermatitis	0.000221	0.000521	CcSEcCtD
Valsartan—Vomiting—Methylprednisolone—atopic dermatitis	0.00022	0.00052	CcSEcCtD
Valsartan—Nausea—Hydrocortisone—atopic dermatitis	0.000219	0.000517	CcSEcCtD
Valsartan—Rash—Triamcinolone—atopic dermatitis	0.000219	0.000516	CcSEcCtD
Valsartan—Dermatitis—Triamcinolone—atopic dermatitis	0.000219	0.000516	CcSEcCtD
Valsartan—Rash—Methylprednisolone—atopic dermatitis	0.000218	0.000515	CcSEcCtD
Valsartan—Dermatitis—Methylprednisolone—atopic dermatitis	0.000218	0.000515	CcSEcCtD
Valsartan—Urticaria—Prednisone—atopic dermatitis	0.000218	0.000514	CcSEcCtD
Valsartan—Headache—Triamcinolone—atopic dermatitis	0.000217	0.000513	CcSEcCtD
Valsartan—Headache—Methylprednisolone—atopic dermatitis	0.000217	0.000512	CcSEcCtD
Valsartan—Abdominal pain—Prednisone—atopic dermatitis	0.000217	0.000512	CcSEcCtD
Valsartan—Diarrhoea—Betamethasone—atopic dermatitis	0.000215	0.000508	CcSEcCtD
Valsartan—Diarrhoea—Dexamethasone—atopic dermatitis	0.000215	0.000508	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—CCR3—atopic dermatitis	0.000214	0.00609	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCL22—atopic dermatitis	0.000209	0.00595	CbGpPWpGaD
Valsartan—Dizziness—Betamethasone—atopic dermatitis	0.000208	0.000491	CcSEcCtD
Valsartan—Dizziness—Dexamethasone—atopic dermatitis	0.000208	0.000491	CcSEcCtD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—SLC11A1—atopic dermatitis	0.000207	0.0059	CbGpPWpGaD
Valsartan—Nausea—Triamcinolone—atopic dermatitis	0.000206	0.000486	CcSEcCtD
Valsartan—Nausea—Methylprednisolone—atopic dermatitis	0.000206	0.000485	CcSEcCtD
Valsartan—AGTR1—GPCR downstream signaling—CCL27—atopic dermatitis	0.000205	0.00584	CbGpPWpGaD
Valsartan—Hypersensitivity—Prednisone—atopic dermatitis	0.000202	0.000477	CcSEcCtD
Valsartan—Vomiting—Dexamethasone—atopic dermatitis	0.0002	0.000472	CcSEcCtD
Valsartan—Vomiting—Betamethasone—atopic dermatitis	0.0002	0.000472	CcSEcCtD
Valsartan—Rash—Dexamethasone—atopic dermatitis	0.000199	0.000469	CcSEcCtD
Valsartan—Rash—Betamethasone—atopic dermatitis	0.000199	0.000469	CcSEcCtD
Valsartan—Dermatitis—Betamethasone—atopic dermatitis	0.000198	0.000468	CcSEcCtD
Valsartan—Dermatitis—Dexamethasone—atopic dermatitis	0.000198	0.000468	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL10—atopic dermatitis	0.000198	0.00565	CbGpPWpGaD
Valsartan—Headache—Dexamethasone—atopic dermatitis	0.000197	0.000466	CcSEcCtD
Valsartan—Headache—Betamethasone—atopic dermatitis	0.000197	0.000466	CcSEcCtD
Valsartan—Asthenia—Prednisone—atopic dermatitis	0.000197	0.000464	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—TNF—atopic dermatitis	0.000195	0.00555	CbGpPWpGaD
Valsartan—Pruritus—Prednisone—atopic dermatitis	0.000194	0.000458	CcSEcCtD
Valsartan—ALB—Folate Metabolism—IL4—atopic dermatitis	0.000193	0.00548	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—TAC1—atopic dermatitis	0.000191	0.00543	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—NPS—atopic dermatitis	0.000191	0.00543	CbGpPWpGaD
Valsartan—Diarrhoea—Prednisone—atopic dermatitis	0.000188	0.000443	CcSEcCtD
Valsartan—Nausea—Dexamethasone—atopic dermatitis	0.000187	0.000441	CcSEcCtD
Valsartan—Nausea—Betamethasone—atopic dermatitis	0.000187	0.000441	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—CXCR3—atopic dermatitis	0.000187	0.00532	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCL27—atopic dermatitis	0.000186	0.0053	CbGpPWpGaD
Valsartan—Dizziness—Prednisone—atopic dermatitis	0.000181	0.000428	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR5—atopic dermatitis	0.00018	0.00511	CbGpPWpGaD
Valsartan—Vomiting—Prednisone—atopic dermatitis	0.000174	0.000411	CcSEcCtD
Valsartan—Rash—Prednisone—atopic dermatitis	0.000173	0.000408	CcSEcCtD
Valsartan—Dermatitis—Prednisone—atopic dermatitis	0.000173	0.000408	CcSEcCtD
Valsartan—Headache—Prednisone—atopic dermatitis	0.000172	0.000405	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL5—atopic dermatitis	0.000171	0.00486	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCL17—atopic dermatitis	0.000167	0.00475	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	0.000165	0.0047	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—TRPV3—atopic dermatitis	0.000164	0.00466	CbGpPWpGaD
Valsartan—Nausea—Prednisone—atopic dermatitis	0.000163	0.000384	CcSEcCtD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	0.000157	0.00446	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR5—atopic dermatitis	0.000154	0.00438	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CXCL10—atopic dermatitis	0.000151	0.0043	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IFNG—atopic dermatitis	0.000143	0.00407	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—CXCL8—atopic dermatitis	0.000139	0.00395	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCL11—atopic dermatitis	0.000135	0.00383	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FCER2—atopic dermatitis	0.000133	0.00378	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CCL5—atopic dermatitis	0.00013	0.0037	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IL1B—atopic dermatitis	0.000128	0.00363	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL22—atopic dermatitis	0.000123	0.00351	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CCR3—atopic dermatitis	0.000121	0.00344	CbGpPWpGaD
Valsartan—ALB—SLC-mediated transmembrane transport—SLC11A1—atopic dermatitis	0.000118	0.00337	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CCR5—atopic dermatitis	0.000117	0.00334	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IFNG—atopic dermatitis	0.000116	0.00331	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL27—atopic dermatitis	0.00011	0.00313	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCR3—atopic dermatitis	0.00011	0.00312	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GLB1—atopic dermatitis	0.000109	0.00312	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—TAC1—atopic dermatitis	0.000108	0.00307	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—NPS—atopic dermatitis	0.000108	0.00307	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCR3—atopic dermatitis	0.000106	0.00301	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	0.000105	0.003	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ADSL—atopic dermatitis	0.000105	0.00299	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL1B—atopic dermatitis	0.000104	0.00296	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL2—atopic dermatitis	0.000103	0.00294	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IL5—atopic dermatitis	0.000103	0.00293	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—IL5—atopic dermatitis	0.0001	0.00285	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL17—atopic dermatitis	9.86e-05	0.00281	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—NPS—atopic dermatitis	9.78e-05	0.00278	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—TAC1—atopic dermatitis	9.78e-05	0.00278	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCR3—atopic dermatitis	9.59e-05	0.00273	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	9.44e-05	0.00269	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	9.3e-05	0.00265	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—TNF—atopic dermatitis	9.26e-05	0.00264	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IFNG—atopic dermatitis	9.24e-05	0.00263	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL5—atopic dermatitis	9.09e-05	0.00259	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KIF3A—atopic dermatitis	8.79e-05	0.0025	CbGpPWpGaD
Valsartan—ALB—Hemostasis—KIF3A—atopic dermatitis	8.69e-05	0.00247	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCL10—atopic dermatitis	8.54e-05	0.00243	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IL1B—atopic dermatitis	8.25e-05	0.00235	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	7.98e-05	0.00227	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CMA1—atopic dermatitis	7.95e-05	0.00226	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL11—atopic dermatitis	7.95e-05	0.00226	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCL10—atopic dermatitis	7.75e-05	0.00221	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	7.72e-05	0.0022	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—PPARA—atopic dermatitis	7.58e-05	0.00216	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TNF—atopic dermatitis	7.53e-05	0.00214	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—STAT6—atopic dermatitis	7.47e-05	0.00213	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—IL6—atopic dermatitis	7.47e-05	0.00213	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GLB1—atopic dermatitis	7.35e-05	0.00209	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CCL5—atopic dermatitis	7.35e-05	0.00209	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CXCL8—atopic dermatitis	7.08e-05	0.00202	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atopic dermatitis	7.05e-05	0.00201	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ADSL—atopic dermatitis	7.05e-05	0.00201	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SELE—atopic dermatitis	7e-05	0.00199	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCL5—atopic dermatitis	6.67e-05	0.0019	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CCR5—atopic dermatitis	6.62e-05	0.00188	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCR3—atopic dermatitis	6.48e-05	0.00185	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—IL6—atopic dermatitis	6.08e-05	0.00173	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCR5—atopic dermatitis	6.01e-05	0.00171	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	6.01e-05	0.00171	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—TNF—atopic dermatitis	5.98e-05	0.0017	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NPS—atopic dermatitis	5.78e-05	0.00164	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TAC1—atopic dermatitis	5.78e-05	0.00164	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCR3—atopic dermatitis	5.66e-05	0.00161	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL5—atopic dermatitis	5.37e-05	0.00153	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	5.36e-05	0.00153	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL5—atopic dermatitis	5.31e-05	0.00151	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—PPARA—atopic dermatitis	5.1e-05	0.00145	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—IL6—atopic dermatitis	4.83e-05	0.00138	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL10—atopic dermatitis	4.58e-05	0.0013	CbGpPWpGaD
Valsartan—ALB—Metabolism—GLB1—atopic dermatitis	4.2e-05	0.0012	CbGpPWpGaD
Valsartan—ALB—Metabolism—ADSL—atopic dermatitis	4.03e-05	0.00115	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCL8—atopic dermatitis	4e-05	0.00114	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL5—atopic dermatitis	3.94e-05	0.00112	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—IL2—atopic dermatitis	3.93e-05	0.00112	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—IL2—atopic dermatitis	3.82e-05	0.00109	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NGF—atopic dermatitis	3.65e-05	0.00104	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCL8—atopic dermatitis	3.63e-05	0.00103	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARA—atopic dermatitis	3.55e-05	0.00101	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCR5—atopic dermatitis	3.55e-05	0.00101	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL2—atopic dermatitis	3.47e-05	0.000989	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GLB1—atopic dermatitis	3.44e-05	0.000979	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ADSL—atopic dermatitis	3.3e-05	0.000939	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	3.06e-05	0.000872	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NFKBIA—atopic dermatitis	3.01e-05	0.000857	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—PPARA—atopic dermatitis	2.91e-05	0.000829	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	2.51e-05	0.000714	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARA—atopic dermatitis	2.39e-05	0.00068	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL8—atopic dermatitis	2.15e-05	0.000611	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL2—atopic dermatitis	2.05e-05	0.000584	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—atopic dermatitis	2.04e-05	0.000581	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL2—atopic dermatitis	2.03e-05	0.000577	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAPK8—atopic dermatitis	1.89e-05	0.000538	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARA—atopic dermatitis	1.36e-05	0.000388	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—atopic dermatitis	1.21e-05	0.000343	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARA—atopic dermatitis	1.12e-05	0.000318	CbGpPWpGaD
